ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.89
0.70%
US Tech 100
18,062.00
-0.10%
S&P 500
5,303.27
0.12%
US Dollar vs CAD
1.36161
0.03%
Bitcoin
66,180.40
-1.14%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Iovance Biotherapeutics Inc (IOVA)

  7. Iovance Biotherapeutics Inc (IOVA) News

IOVA

Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IOVA
DateTimeSourceHeadlineSymbolCompany
05/17/20244:15PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:IOVAIovance Biotherapeutics Inc
05/17/20244:15PMGlobeNewswire Inc.Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:IOVAIovance Biotherapeutics Inc
05/09/20244:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOVAIovance Biotherapeutics Inc
05/09/20244:10PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IOVAIovance Biotherapeutics Inc
05/09/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOVAIovance Biotherapeutics Inc
05/09/20243:01PMGlobeNewswire Inc.Iovance Biotherapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:IOVAIovance Biotherapeutics Inc
05/01/20245:01AMGlobeNewswire Inc.Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024NASDAQ:IOVAIovance Biotherapeutics Inc
04/30/20245:01AMGlobeNewswire Inc.Iovance Biotherapeutics to Present at Upcoming ConferencesNASDAQ:IOVAIovance Biotherapeutics Inc
04/24/20243:01PMGlobeNewswire Inc.Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual MeetingNASDAQ:IOVAIovance Biotherapeutics Inc
04/19/20244:15PMGlobeNewswire Inc.Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:IOVAIovance Biotherapeutics Inc
03/22/20244:30PMGlobeNewswire Inc.Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:IOVAIovance Biotherapeutics Inc
03/06/20245:17PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOVAIovance Biotherapeutics Inc
03/05/20244:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOVAIovance Biotherapeutics Inc
03/05/20244:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOVAIovance Biotherapeutics Inc
03/05/20244:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOVAIovance Biotherapeutics Inc
03/05/20244:52PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOVAIovance Biotherapeutics Inc
03/05/20244:51PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOVAIovance Biotherapeutics Inc
03/05/20244:50PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOVAIovance Biotherapeutics Inc
03/04/20247:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOVAIovance Biotherapeutics Inc
03/04/20245:30AMGlobeNewswire Inc.Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung CancerNASDAQ:IOVAIovance Biotherapeutics Inc
03/01/20244:00PMGlobeNewswire Inc.Iovance Biotherapeutics to Present at Upcoming ConferencesNASDAQ:IOVAIovance Biotherapeutics Inc
02/29/20246:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOVAIovance Biotherapeutics Inc
02/28/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOVAIovance Biotherapeutics Inc
02/28/20243:01PMGlobeNewswire Inc.Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates NASDAQ:IOVAIovance Biotherapeutics Inc
02/22/20243:53PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOVAIovance Biotherapeutics Inc
02/22/20247:45AMGlobeNewswire Inc.Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024NASDAQ:IOVAIovance Biotherapeutics Inc
02/21/20243:44PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IOVAIovance Biotherapeutics Inc
02/20/20244:23PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:IOVAIovance Biotherapeutics Inc
02/20/20243:21PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IOVAIovance Biotherapeutics Inc
02/20/20245:30AMGlobeNewswire Inc.Iovance Biotherapeutics, Inc. Announces Pricing of $211 Million Underwritten Offering of Common StockNASDAQ:IOVAIovance Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:IOVA

Your Recent History

GATE
LEMDETH
lemond.money
BIT
1EW
Edwards Lifesciences
ASX
NDXMOY
BTHB
HYCKRW
HYCON
EU
ISJET
Leverage Shares 3x Short...
KOSPI
002410
Pumyang Construction
EU
IVLUD
BNPP Vlud iNav
BIT
UI681C
Unicredit Bank
COIN
EOGETH
Eye of God
NASDAQ
JCOM
j2 Global
SUSHI
BASKETH
BasketDAO Gov
USOTC
SMSSY
SMS (PK)
LSE
52HM
Nie Fin. 2.500%
COIN
DRSUST
BIT
P1JO88
BNP Paribas Issuance BV
LBNK
STORJUSDT
Storj
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved